Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  United Therapeutics Corporation    UTHR   US91307C1027

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo United Therapeutics Corpor
Develops pharmaceutical products

United Therapeutics Corp. operates as a biotechnology company, which focuses on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

The company operates in two business segments: Pharmaceuticals and Telemedicine.

Its primary product Remodulin is used for the treatment of pulmonary arterial hypertension and the company also develops glycol-biological antiviral agents for the treatment of infectious diseases, such as Hepatitis C. United Therapeutics was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Number of employees : 706 persons.
Sales per Businesses
20122013Delta
USD (in Million)%USD (in Million)%
Pharmaceutical916.08100.2%1,117100% +17.99%
Sales per Regions
20122013Delta
USD (in Million)%USD (in Million)%
United States846.6192.6%1,03292.4% +18%
Rest-of-World69.477.6%84.557.6% +17.84%
Managers
NameAgeSinceTitle
Martine A. Rothblatt PhD, MBA591996Chairman & Chief Executive Officer
Roger A. Jeffs, PhD521998President, Chief Operating Officer & Director
John Maxim Ferrari592001Chief Financial Officer & Treasurer
Shola Oyewole-2000Chief Information Officer
Raymond C. Kurzweil, PhD662002Director
Louis Wade Sullivan, MD802013Independent Director
Raymond Allen Dwek722002Director
Christopher Patusky502002Vice Chairman
Christopher Causey, MBA512003Independent Director
Richard Giltner502009Independent Director
Shareholders
NameShares%
Fidelity Management & Research Co. 4,491,6789.50%
BlackRock Fund Advisors 3,631,8667.68%
The Vanguard Group, Inc. 2,829,0535.99%
AJO LP 2,060,9604.36%
LSV Asset Management 1,895,3284.01%
Acadian Asset Management LLC 1,881,7833.98%
BlackRock Advisors LLC 1,387,0152.93%
SSgA Funds Management, Inc. 1,383,6862.93%
TimesSquare Capital Management LLC 1,308,9002.77%
Palo Alto Investors LLC 1,213,8282.57%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
PHARMACYCLICS, IN..
INCYTE CORPORATIO..
QUINTILES TRANSNA..
PUMA BIOTECHNOLOG..
-
ALNYLAM PHARMACEU..
ALKERMES PLC
UNITED THERAPEUTI..
QIAGEN NV
ISIS PHARMACEUTIC..
COVANCE INC.
SEATTLE GENETICS,..
ICON PLC
TECHNE CORPORATIO..
PAREXEL INTERNATI..
CHARLES RIVER LAB..
ACADIA PHARMACEUT..
SYNAGEVA BIOPHARM..
WUXI PHARMATECH (..
MORPHOSYS AG
BB BIOTECH AG
Sector Biotechnology & Medical Research
Company contact information
United Therapeutics Corp.
1040 Spring Street
Silver Spring, MD 20910

Phone : +1.301.608.9292
Fax : +1.301.608.9291
Web : www.unither.com
© 2014 Factset   
Dynamic quotes  
ON
| OFF